The FY24 PRCRP ACCCTA supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY24 PRCRP Topic Areas. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials to determine efficacy in relevant patient populations.
Funding from this award mechanism must support a clinical trial.
Deadlines:
- Required Pre-Application Submission Deadline: July 24, 2024
- Invitation to Submit an Application: August 2024
- Application Submission Deadline: October 15, 2024
To be considered for funding, applications for the FY24 PRCRP Advancing Cancer Care Through Clinical Trials Award (ACCCTA) must address at least one of the congressionally directed FY24 PRCRP Topic Areas. Congressional language stipulates the FY24 PRCRP must not address research in melanoma, glioblastoma, or cancers originating in the breast, pancreas, prostate, ovary, kidney, or lung. In addition, FY24 PRCRP funds must not be used to study rare cancers except for subtypes of the FY24 PRCRP Topic Areas that are rare by definition. Applicants are directed to apply to the individual CDMRP cancer programs in those disease areas. The FY24 PRCRP Topic Areas are listed below.
• Bladder cancer
• Blood cancers
• Brain cancer (excluding glioblastoma)
• Colorectal cancer
• Endometrial cancer
• Esophageal cancer
• Germ cell cancers
• Liver cancer
• Lymphoma
• Mesothelioma
• Metastatic cancers
• Myeloma
• Neuroblastoma
• Pediatric, adolescent, and young adult cancers1
• Pediatric brain tumors
• Stomach cancer
• Sarcoma
• Thyroid cancer
Independent investigators at or above the level of Assistant Professor (or equivalent) are eligible to be named as the Principal Investigator (PI) on the application.
An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY24 PRCRP Advancing Cancer Care Through Clinical Trials Award should not exceed $3,000,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.